Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:DRTS NASDAQ:SKIN NASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.38+1.8%$3.76$1.60▼$16.31$251.01M1.2923,000 shs522,165 shsDRTSAlpha Tau Medical$3.53+1.4%$3.16$2.11▼$4.39$299.42M163,568 shs94,062 shsSKINBeauty Health$2.00$1.95$0.78▼$2.56$253.64M1.23844,893 shs511,985 shsVANIVivani Medical$1.16$1.35$0.91▼$1.80$68.72M3.12103,629 shs15,397 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-1.19%-7.78%-9.78%+6.07%-78.99%DRTSAlpha Tau Medical+1.75%+4.82%+16.78%+18.37%+42.04%SKINBeauty Health-3.85%-1.48%+30.72%+19.76%+11.73%VANIVivani Medical+0.87%-3.33%-12.78%+3.57%-11.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.9528 of 5 stars3.62.00.00.02.50.80.0DRTSAlpha Tau Medical2.2102 of 5 stars3.53.00.00.01.71.70.0SKINBeauty Health1.7065 of 5 stars3.00.00.00.02.83.30.0VANIVivani Medical3.0502 of 5 stars3.55.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56271.47% UpsideDRTSAlpha Tau Medical 3.00Buy$9.00154.96% UpsideSKINBeauty Health 2.00Hold$2.6331.25% UpsideVANIVivani Medical 3.00Buy$4.00244.83% UpsideCurrent Analyst Ratings BreakdownLatest VANI, DRTS, CATX, and SKIN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.009/2/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.008/1/2025SKINBeauty HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.00 ➝ $4.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ADRTSAlpha Tau MedicalN/AN/AN/AN/A$1.02 per shareN/ASKINBeauty Health$334.30M0.76$0.06 per share32.90$0.58 per share3.45VANIVivani MedicalN/AN/AN/AN/A$0.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.48N/AN/AN/AN/A-51.21%-38.18%11/18/2025 (Estimated)SKINBeauty Health-$29.10M-$0.28N/AN/AN/A-6.13%-32.82%-2.96%11/11/2025 (Estimated)VANIVivani Medical-$23.49M-$0.45N/AN/AN/AN/A-194.66%-68.64%11/12/2025 (Estimated)Latest VANI, DRTS, CATX, and SKIN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VANIVivani Medical-$0.10-$0.12-$0.02-$0.12N/AN/A8/11/2025Q2 2025DRTSAlpha Tau Medical-$0.12-$0.13-$0.01-$0.13N/AN/A8/7/2025Q2 2025SKINBeauty Health-$0.06$0.03+$0.09$0.03$74.67 million$78.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60DRTSAlpha Tau Medical0.0710.525.81SKINBeauty Health4.915.154.15VANIVivani MedicalN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%DRTSAlpha Tau Medical2.65%SKINBeauty Health93.26%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.52%DRTSAlpha Tau Medical39.50%SKINBeauty Health41.00%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataSKINBeauty Health1,030126.82 million74.83 millionOptionableVANIVivani Medical2059.24 million31.76 millionOptionableVANI, DRTS, CATX, and SKIN HeadlinesRecent News About These CompaniesA brewing GLP-1 showdown, from Big Pharma pills to a biotech implantAugust 27, 2025 | finance.yahoo.comOzempic for dogs? I’d happily put my food-obsessed golden retriever on ‘Wagovy’August 24, 2025 | aol.comAAre weight-loss jabs for dogs the next big thing? Scientists exploring new solutions for pet obesityAugust 22, 2025 | msn.comOzempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We KnowAugust 22, 2025 | msn.comCould Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet ObesityAugust 21, 2025 | ndtv.comNAfter Ozempic, is “Ozempup” on the way? Scientists explore weight-loss jabs for obese pet dogs-- All details hereAugust 21, 2025 | msn.comVivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant TechnologyAugust 20, 2025 | quiverquant.comQVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025August 20, 2025 | globenewswire.comFido get fat? Ozempic for dogs could hit the market in three yearsAugust 19, 2025 | msn.comVivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings MissAugust 15, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comVivani closes $10M financing, advances GLP-1 implantAugust 14, 2025 | drugdeliverybusiness.comDVivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deVivani Medical Reports Q2 2025 Results and $10M FinancingAugust 13, 2025 | tipranks.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...August 13, 2025 | bakersfield.comBVivani Medical Secures $10M Through Share Purchase AgreementAugust 13, 2025 | msn.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comVivani Medical (VANI) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.com3 Penny Stocks With Market Caps Over $30M To ConsiderJuly 16, 2025 | finance.yahoo.comVivani Medical Insiders Added US$5.29m Of Stock To Their HoldingsJune 30, 2025 | uk.finance.yahoo.comVivani Medical shareholders elect board and approve key proposals at annual meeting - Investing.comJune 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVANI, DRTS, CATX, and SKIN Company DescriptionsPerspective Therapeutics NYSE:CATX$3.38 +0.06 (+1.81%) Closing price 04:00 PM EasternExtended Trading$3.40 +0.02 (+0.44%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Alpha Tau Medical NASDAQ:DRTS$3.53 +0.05 (+1.44%) Closing price 04:00 PM EasternExtended Trading$3.60 +0.07 (+1.84%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Beauty Health NASDAQ:SKIN$2.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.Vivani Medical NASDAQ:VANI$1.16 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.16 0.00 (0.00%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
